Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

AstraZeneca plc

Start price
Target price
Perf. (%)
€94.00
€78.00
1.117%

Sorrento Therapeutics Inc.

Start price
Target price
Perf. (%)
€8.17
€12.00
12.674%

Could be worthwhile Investment >10% per year
Very Future proof/growth oriented business model
Novavax Inc.

Start price
Target price
Perf. (%)
€91.29
-
4.305%

Could be worthwhile Investment >10% per year
Little known brand
Trillium Therapeutics

Start price
Target price
Perf. (%)
€8.28
-
50.966%

Could be very worthwhile Investment >20% year
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€128.00
€135.00
-0.031%

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Higher risks for its business
Novavax Inc.

Start price
Target price
Perf. (%)
€80.99
-
17.570%

Could be very worthwhile Investment >20% year
Cocrystal Pharma Inc.

Start price
Target price
Perf. (%)
€0.73
-
23.448%

Could be very worthwhile Investment >20% year
Grifols S.A.

Start price
Target price
Perf. (%)
€22.77
€28.00
1.888%

Could be worthwhile Investment >10% per year
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€55.32
€50.00
-1.096%

Known brand
Probably not worthwhile Investment
Significant cyclical dependencies
Revenue decline/stagnation expected
Seres Therapeutics Inc

Start price
Target price
Perf. (%)
€21.00
€12.00
6.667%

Probably not worthwhile Investment
Kazia Therapeutics ADR

Start price
Target price
Perf. (%)
€6.50
-
-13.846%

Probably not worthwhile Investment
iBio Inc.

Start price
Target price
Perf. (%)
€1.47
-
31.293%

Risky Investment
AstraZeneca plc

Start price
Target price
Perf. (%)
€95.39
€105.50
-0.356%

Future proof or reliable business model
Small cyclical dependencies
Known brand
Organovo Holdings Inc.

Start price
Target price
Perf. (%)
€5.76
€0.000
0.000%

Bayer AG

Start price
Target price
Perf. (%)
€57.13
€80.00
-4.674%

Could be worthwhile Investment >10% per year
Innovative
Medium risks for its business
Known brand
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€58.10
-
-5.828%

Could be worthwhile Investment >10% per year
Capable Management
Innovative
Market Leader or Top 3
iBio Inc.

Start price
Target price
Perf. (%)
€2.16
€1.00
-10.648%

Risky Investment
Revenue decline > 20% expected
EBIT decline > 20% expected
very negative Cash Flow expected
Abbott Laboratories

Start price
Target price
Perf. (%)
€85.17
-
5.037%

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth > 30% per year expected
Seelos Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.87
€1.00
-38.673%

Could be worthwhile Investment >10% per year
CytoTools AG

Start price
Target price
Perf. (%)
€10.20
€26.00
35.784%

Could be very worthwhile Investment >20% year
Differentiated customer and product portfolio
Seattle Genetics

Start price
Target price
Perf. (%)
€132.84
€153.00
16.893%

Could be very worthwhile Investment >20% year
Omeros Corp.

Start price
Target price
Perf. (%)
€13.45
€23.00
-26.263%

Could be very worthwhile Investment >20% year
Verastem Inc.

Start price
Target price
Perf. (%)
€1.27
€2.00
-12.480%

Could be worthwhile Investment >10% per year
Heat Biologics Inc.

Start price
Target price
Perf. (%)
€1.73
-
-30.636%

Risky Investment
Morphosys AG

Start price
Target price
Perf. (%)
€108.25
€130.00
2.263%